Cassava Sciences, Inc (SAVA)

Etorro trading 970x250

About Cassava Sciences, Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas. Address: 7801 North Capital of Texas Highway, Austin, TX, United States, 78731

Cassava Sciences, Inc News and around…

Latest news about Cassava Sciences, Inc (SAVA) common stock and company :

The 7 Best Meme Stocks to Buy Now
25 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The meme stock craze might never be what it was last year, but these meme stocks to buy that are still worth another look. The post The 7 Best Meme Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
24 May, 2022 FinancialContent

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur ...

Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
24 May, 2022 FinancialContent
Noteworthy Monday Option Activity: PRDO, SAVA, TRTX
23 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Perdoceo Education Corp (PRDO), where a total volume of 5,192 contracts has been traded thus far today, a contract volume which is representative of approximately 519,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 81.6% of PRDO's average daily trading volume over the past month, of 636,295 shares..

Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop
23 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks continue to be of interest to retail traders looking to pump up shares while pushing hedge funds out of a company. The post Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Notable Friday Option Activity: VUZI, ENPH, SAVA
13 May, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vuzix Corp (VUZI), where a total of 7,941 contracts have traded so far, representing approximately 794,100 underlying shares. That amounts to about 50.5% of VUZI's average daily trading volume over the past month of 1.6 million shares..

How Is The Market Feeling About Cassava Sciences?
12 May, 2022 FinancialContent

Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has ...

July 1st Options Now Available For Cassava Sciences
12 May, 2022 FinancialContent

Investors in Cassava Sciences Inc (SAVA) saw new options begin trading today, for the July 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new July 1st contracts and identified one put and one call contract of particular interest.

June 24th Options Now Available For Cassava Sciences (SAVA)
05 May, 2022 FinancialContent

Investors in Cassava Sciences Inc (SAVA) saw new options become available today, for the June 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new June 24th contracts and identified one put and one call contract of particular interest.

Recap: Cassava Sciences Q1 Earnings
05 May, 2022 FinancialContent

Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what ...

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
05 May, 2022 Yahoo! Finance

- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida

What Are Whales Doing With Cassava Sciences
04 May, 2022 FinancialContent

Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We ...

Cassava Sciences May Be Heading Below $10 Per Share
04 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall. The post Cassava Sciences May Be Heading Below $10 Per Share appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
03 May, 2022 FinancialContent

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average ...

Implied XPH Analyst Target Price: $62
02 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $62.49 per unit.

Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
29 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
28 Apr, 2022 Yahoo! Finance

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.

SAVA June 10th Options Begin Trading
28 Apr, 2022 FinancialContent

Investors in Cassava Sciences Inc (SAVA) saw new options become available today, for the June 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new June 10th contracts and identified one put and one call contract of particular interest.

Noteworthy Tuesday Option Activity: SAVA, ALNY, GME
26 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cassava Sciences Inc (SAVA), where a total of 17,321 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 73.7% of SAVA's average daily trading volume over the past month of 2.4 million shares..

Take Full Advantage of Weakness in Cassava Sciences Stock
26 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again. The post Take Full Advantage of Weakness in Cassava Sciences Stock appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Cassava Sciences Is a Worthwhile Bet to Consider
25 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
25 Apr, 2022 Yahoo! Finance

- Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
22 Apr, 2022 FinancialContent

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns whether Cassava has violated the federal securities laws and/or engaged in other unlawful business practices.

June 3rd Options Now Available For Cassava Sciences (SAVA)
21 Apr, 2022 FinancialContent

Investors in Cassava Sciences Inc (SAVA) saw new options become available today, for the June 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAVA options chain for the new June 3rd contracts and identified one put and one call contract of particular interest.

The Crowd Has Wisely Soured on Cassava Sciences Stock
20 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

54 Biggest Movers From Yesterday
20 Apr, 2022 FinancialContent

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron ...

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
19 Apr, 2022 Yahoo! Finance

Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US). In this article, we will review Cassava's product line and cash capacity to fund further research until FDA approval.

12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Apr, 2022 FinancialContent

Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular ...

$1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much
19 Apr, 2022 FinancialContent

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 19.11% on an annualized basis producing an average ...

38 Stocks Moving In Tuesday's Mid-Day Session
19 Apr, 2022 FinancialContent

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: ...

Cassava Sciences, Inc (SAVA) is a NASDAQ Common Stock listed in , ,

970x250